M. Domine Gomez - IIS Hosp Fdn Jimenez Diaz, Madrid, Spain

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 41 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

209P Small cell lung cancer in never smokers: A descriptive analysis

A. Ruano-Ravina, C. Candal Pedreira,V. Calvo de Juan,M. Cobo Dols,J.M. Trigo Perez,D. Rodriguez Abreu, A. Estival Gonzalez, E. Carcereny,M. Cucurull Salamero, R. López Castro,M.R. García Campelo, P. Cordeiro González,

ESMO Open (2024)

引用0浏览0引用

12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial

M. Frueh, R.A. Soo, A. Vervita,B.C. Cho, M. Majem,D. Rodriguez Abreu, A. Callejo Perez,M.T. Moran Bueno,M. Domine Gomez,M. Provencio Pulla, A. Addeo,J-Y. Han,

ESMO Open (2024)

引用0浏览0引用

251P Sexual dysfunction in patients with lung cancer: Interim analysis of the LUDICAS study

A.V. Ospina Serrano, P. Guillén Sentís, E. Azkona, F.D.A. Aparisi Aparisi, R. Lopez,M. Domine Gomez, A. Olivares Hernandez, M. Antonanzas Basa, P. Cruz Castellanos,A. Blasco Cordellat, A. Cardena, A. Valdivia,

ESMO Open (2024)

引用0浏览0引用

1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

E. Felip, M.G. Krebs, E. Carcereny, K.B. Smeland, E. Arriola,C. Llacer Perez,J. Thompson, L. Paz-Ares,M. Domine Gomez, J.R. Olivares,N. Vinolas Segarra,M.R. García-Campelo,

Annals of Oncology (2023): S819-S819

引用0浏览0引用

Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC

M. Domine Gomez,M. Cobo Dols,J. de Castro,A. Moreno Vega,S. Ponce Aix,E. Arriola,E. Carcereny,M. Majem Tarruella,G. Huidobro Vence,E. Esteban Gonzalez,J. Fuentes Pradera,A. L. Ortega Granados,

Journal of Thoracic Oncologyno. 11 (2023): S370-S371

引用0浏览0引用

Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

B. Sierra-Rodero, C. Martinez-Toledo,M. Molina-Alejandre, V. Calvo,E. Nadal,B. Massuti Sureda,R. Garcia Campelo,C. Gonzalez Ojea, A. Martinez-Marti,M. Domine Gomez,S. Ponce Aix,M. A. Insa Molla,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S141-S142

引用0浏览0引用

Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study

R. Garcia-Campelo,M. Domine Gomez,J. de Castro,A. Moreno Vega,S. Ponce Aix,E. Arriola, E. Carcereny,M. Majem Tarruella, G. Huidobro Vence, E. Esteban Gonzalez,J. Fuentes Pradera,A. L. Ortega Granados,

Journal of Thoracic Oncologyno. 11 (2023): S372-S372

引用0浏览0引用

1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

M.R. Garcia Campelo,M. Domine Gomez,J. De Castro Carpeno,A.L. Moreno Vega,S. Ponce Aix, E. Arriola,E. Carcereny Costa,M. Majem Tarruella, G. Huidobro Vence,E. Esteban Gonzalez,J. Fuentes Pradera,A.L.O. Ortega Granados,

Annals of Oncology (2022): S1246-S1247

引用3浏览0引用

102P Clinical analysis of patients with different KRAS mutations in NSCLC: Different entities analyzed by NGS

J. Rubio Perez, M. Fernández Ochoa, P.L. Villalba Cuesta, M. Avedillo Ruidiaz,F. Rojo,M. Domine Gomez

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn